Nanoparticle Packaging Dramatically Increases Potency of Anti-Cardiovascular Disease Drug
|
By LabMedica International staff writers Posted on 06 Jul 2015 |
![Image: The buildup of fatty substances in blood vessels caused by atherosclerosis stiffens and narrows the blood vessels resulting in the death of heart muscle (Photo courtesy of [US] National Heart, Lung, and Blood Institute). Image: The buildup of fatty substances in blood vessels caused by atherosclerosis stiffens and narrows the blood vessels resulting in the death of heart muscle (Photo courtesy of [US] National Heart, Lung, and Blood Institute).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2015-07-06/GMS-208.jpg)
Image: The buildup of fatty substances in blood vessels caused by atherosclerosis stiffens and narrows the blood vessels resulting in the death of heart muscle (Photo courtesy of [US] National Heart, Lung, and Blood Institute).
The use of biodegradable polymer nanoparticles to encapsulate a promising drug for treating atherosclerosis increased its residence time in the body of a treated mouse from less than one hour to at least four hours (and up to 48 hours or longer).
The drug, D-PDMP (D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol), is a glycosphingolipid synthesis inhibitor. Previous studies had shown that it held considerable promise for the treatment of atherosclerosis and cardiac hypertrophy, but rapid in vivo clearance severely hindered its use in the clinical setting.
To overcome this impediment, investigators at Johns Hopkins University (Baltiomore, MD, USA) sequestered D-PDMP inside a biodegradable polymer composed of polyethylene glycol (PEG) and sebacic acid (SA).
Some PEG-SA nanoparticles were labeled with PEG that contained a radioactive iodine tracer to allow in vivo bio-distribution and release kinetics of D-PDMP to be determined by using gamma-scintigraphy and subsequently, by mass spectrometry. Results published in the June 3, 2015, online edition of the journal Biomaterials revealed that polymer encapsulation increased the residence time of D-PDMP in the body of a treated mouse from less than one hour to at least four hours (and up to 48 hours or longer).
The substantially increased in vivo longevity provided by polymer encapsulation resulted in a 10-fold gain in the drug's efficacy for interfering with atherosclerosis and cardiac hypertrophy in a model based on mice genetically engineered to lack the gene for the apolipoprotein E receptor that were fed a high fat and high cholesterol diet.
"Our experiments illustrate clearly that while content is important, packaging can make or break a drug," said senior author Dr. Subroto Chatterjee, professor of medicine and pediatrics at Johns Hopkins University. "In our study, the right packaging vastly improved the drug's performance and its ability not merely to prevent disease but to mitigate some of its worst manifestations."
Related Links:
Johns Hopkins University
The drug, D-PDMP (D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol), is a glycosphingolipid synthesis inhibitor. Previous studies had shown that it held considerable promise for the treatment of atherosclerosis and cardiac hypertrophy, but rapid in vivo clearance severely hindered its use in the clinical setting.
To overcome this impediment, investigators at Johns Hopkins University (Baltiomore, MD, USA) sequestered D-PDMP inside a biodegradable polymer composed of polyethylene glycol (PEG) and sebacic acid (SA).
Some PEG-SA nanoparticles were labeled with PEG that contained a radioactive iodine tracer to allow in vivo bio-distribution and release kinetics of D-PDMP to be determined by using gamma-scintigraphy and subsequently, by mass spectrometry. Results published in the June 3, 2015, online edition of the journal Biomaterials revealed that polymer encapsulation increased the residence time of D-PDMP in the body of a treated mouse from less than one hour to at least four hours (and up to 48 hours or longer).
The substantially increased in vivo longevity provided by polymer encapsulation resulted in a 10-fold gain in the drug's efficacy for interfering with atherosclerosis and cardiac hypertrophy in a model based on mice genetically engineered to lack the gene for the apolipoprotein E receptor that were fed a high fat and high cholesterol diet.
"Our experiments illustrate clearly that while content is important, packaging can make or break a drug," said senior author Dr. Subroto Chatterjee, professor of medicine and pediatrics at Johns Hopkins University. "In our study, the right packaging vastly improved the drug's performance and its ability not merely to prevent disease but to mitigate some of its worst manifestations."
Related Links:
Johns Hopkins University
Latest BioResearch News
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
- Population-Scale Proteomics Study Identifies New Genetic-Protein Links
Channels
Clinical Chemistry
view channel
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more
Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read moreMolecular Diagnostics
view channel
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







